Arama Sonuçları - L Rimsky

  • Gösterilen 1 - 15 sonuçlar arası kayıtlar. 15
Sonuçları Daraltın
  1. 1
    Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides

    Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides Yazar: L Rimsky, Diane C. Shugars, Thomas J. Matthews

    Baskı/Yayın Bilgisi 1998
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  2. 2
    96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials

    96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials Yazar: L Rimsky, Veerle Van Eygen, Annemie Hoogstoel, Marita Stevens, Katia Boven, Gastón Picchio, Johan Vingerhoets

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.

    Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor. Yazar: Hiro Wakasugi, L Rimsky, Yann F. Mahé, Azza M. Kamel, D Fradelizi, Thomas Tursz, Jacques Bertoglio

    Baskı/Yayın Bilgisi 1987
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies

    Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies Yazar: L Rimsky, Johan Vingerhoets, Veerle Van Eygen, Joseph J. Eron, Bonaventura Clotet, Annemie Hoogstoel, Katia Boven, Gastón Picchio

    Baskı/Yayın Bilgisi 2011
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors

    Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors Yazar: Lotke Tambuyzer, Hilde Azijn, L Rimsky, Johan Vingerhoets, Pierre Lecocq, Guenter Kraus, Gastón Picchio, Marie‐Pierre de Béthune

    Baskı/Yayın Bilgisi 2009
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Cloning and expression of a cDNA for human thioredoxin.

    Cloning and expression of a cDNA for human thioredoxin. Yazar: E Wollman, L d'Auriol, L Rimsky, Alan Shaw, Jean‐Pierre Jacquot, Paul T. Wingfield, Pierre Graber, Françoise Dessarps, Philippe Robin, Francis Galibert

    Baskı/Yayın Bilgisi 1988
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  7. 7
    The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness

    The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness Yazar: Rima Kulkarni, Kerim Babaoglu, E.B. Lansdon, L Rimsky, Veerle Van Eygen, Gastón Picchio, Evguenia S. Svarovskaia, Michael D. Miller, Kirsten L. White

    Baskı/Yayın Bilgisi 2011
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  8. 8
    TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

    TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 Yazar: Hilde Azijn, Ilse Tirry, Johan Vingerhoets, Marie‐Pierre de Béthune, Guenter Kraus, Katia Boven, Dirk Jochmans, Elke Van Craenenbroeck, Gastón Picchio, L Rimsky

    Baskı/Yayın Bilgisi 2009
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

    Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial Yazar: Anton Pozniak, Javier O Morales-Ramirez, Elly Katabira, Dewald Steyn, Sergio Lupo, Mario Santoscoy, Beatriz Grinsztejn, Kiat Ruxrungtham, L Rimsky, Simon Vanveggel, Katia Boven

    Baskı/Yayın Bilgisi 2009
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  10. 10
    Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1

    Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 Yazar: Marc Girard, Bernard Meignier, Françoise Barré‐Sinoussi, M. P. Kieny, Thomas J. Matthews, Elizabeth Muchmore, Peter L. Nara, Qing Wei, L Rimsky, Kent J. Weinhold

    Baskı/Yayın Bilgisi 1995
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  11. 11
    Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins

    Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins Yazar: Ernst Böhnlein, Miriam Siekevitz, Dean W. Ballard, John W. Lowenthal, L Rimsky, Hal P. Bogerd, J A Hoffman, Yuji Wano, B. Robert Franza, Warner C. Greene

    Baskı/Yayın Bilgisi 1989
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  12. 12
    Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.

    Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Yazar: S M Hanly, L Rimsky, Michael H. Malim, J H Kim, Joachim Hauber, Madeleine Duc Dodon, Shu‐Yun Le, Jacob V. Maizel, Bryan R. Cullen, Warner C. Greene

    Baskı/Yayın Bilgisi 1989
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  13. 13
    Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients

    Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients Yazar: Cal Cohen, Jean‐Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Wei Hao, Margaret Johnson, K Supparatpinyo, HM Crauwels, L Rimsky, Simon Vanveggel, Paige Williams, Katia Boven

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  14. 14
    Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

    Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials Yazar: Calvin Cohen, Jean‐Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Chloe Orkin, Frank S. Rhame, Hans-Jürgen Stellbrink, Taisheng Li, Herta Crauwels, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  15. 15
    Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients

    Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients Yazar: Calvin Cohen, Jean‐Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Hao Wu, Margaret Johnson, Michael S. Saag, Khuanchai Supparatpinyo, Herta Crauwels, Éric Lefebvre, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: